Saturday, January 22nd | 20 Shevat 5782

Subscribe
May 1, 2014 5:13 pm
0

In Case You Didn’t Know: Israel’s Medical Marijuana Market (VIDEO)

avatar by Alina Dain Sharon / JNS.org

Israel's medical Marijuana industry is attracting attention. Photo: Wikimedia Commons.

JNS.org – An interesting CNBC article explores the medical marijuana industry in Israel. Medical marijuana is legal in Israel. According to CNBC, not only is it a $40 million industry in Israel, but Israeli research in the field has fueled the U.S. medical marijuana business, which will be worth an estimated $2 billion by the end of 2014.

Furthermore, Israel’s largest cannabis supplier is a company founded in 2006 called Tikun Olam. The company seeks to provide patients with free marijuana for medical use and has had a license from the Israeli government to grow the plant since 2007. The goal is to provide medial marijuana for everyone who needs it, not only in Israel, but also in Palestinian Authority-controlled territory.

Related coverage

September 7, 2016 6:28 am

Petty Orthodoxy

Thetorah.com is a website that analyzes the weekly reading of the Torah for people who do not take every word in the Torah...

Tikun Olam has about 4,000 patients and 60 employees. Most patients pay the company $100 a month for the medical cannabis and $40 for a tutorial showing how to properly use the drug. For children with cancer, the drug is provided for free.

Other countries are expressing growing interest in Israel’s medical marijuana market. Czech Health Minister Svatopluk Nemecek visited a grower in Israel last month to discuss the possibility of exporting the drug to the Czech Republic. Tikun Olam is collaborating with Canadian Company MedReleaf, and former New York Deputy Comptroller for Budget and Public Affairs Ari Hoffnung visited Tikun Olam in Israel a few months ago to see if it would be possible to replicate the model in New York.

Watch the video below to learn about Israel’s medical marijuana industry:

Share this Story: Share On Facebook Share On Twitter

Let your voice be heard!

Join the Algemeiner

Algemeiner.com

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.